Ellington Management Group’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Ellington Management Group’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-4,900	Closed	-$607K	–	805
2019 Q4	$607K	Buy	4,900 +1,500	+44%	+$134K	0.13%	134
2019 Q3	$226K	Buy	+3,400	New	+$228K	0.04%	456
2019 Q2	–	Sell	-7,100	Closed	-$794K	–	832
2019 Q1	$794K	Buy	+7,100	New	+$776K	0.14%	165
2018 Q3	–	Sell	-2,900	Closed	-$243K	–	737
2018 Q2	$243K	Sell	2,900 -2,200	-43%	-$161K	0.02%	345
2018 Q1	$314K	Buy	+5,100	New	+$307K	0.02%	576
2017 Q3	–	Sell	-2,300	Closed	-$278K	–	908
2017 Q2	$278K	Sell	2,300 -300	-12%	-$34.8K	0.04%	425
2017 Q1	$294K	Buy	+2,600	New	+$304K	0.01%	473
2016 Q1	–	Sell	-2,300	Closed	-$344K	–	744
2015 Q4	$344K	Buy	+2,300	New	+$389K	0.12%	242
2014 Q2	–	Sell	-1,400	Closed	-$462K	–	705
2014 Q1	$462K	Buy	+1,400	New	+$472K	0.14%	236

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Ellington Management Group's ICPT Position: Q1 2020 in Review

Ellington Management Group sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2020, closing a stake of 4,900 shares — an estimated $607K sold.

Ellington Management Group first reported a position in ICPT in Q1 2014 and held it in 9 quarters. The position peaked at $794K in Q1 2019. 188 funds tracked by Wall St. Rank hold ICPT as of Q1 2020.

Ellington Management Group reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Ellington Management Group sold 4,900 Intercept Pharmaceuticals, Inc. shares in Q1 2020, an estimated $607K.
Ellington Management Group first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2014 and held it in 9 quarters.
Ellington Management Group's Intercept Pharmaceuticals, Inc. position peaked at $794K in Q1 2019.
188 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2020.

Based on Ellington Management Group's 13F filing for Q1 2020, filed 15 May 2020.